139 related articles for article (PubMed ID: 29392423)
21. Optic pathway glioma in children: does visual deficit correlate with radiology in focal exophytic lesions?
Aquilina K; Daniels DJ; Spoudeas H; Phipps K; Gan HW; Boop FA
Childs Nerv Syst; 2015 Nov; 31(11):2041-9. PubMed ID: 26277358
[TBL] [Abstract][Full Text] [Related]
22. Effective rescue treatment with vemurafenib of an infant with high-risk Langerhans cell histiocytosis.
Gerbaux M; Diallo S; Dedeken L; Dangoisse C; Bott A; Heritier S; Salik D; Ferster A
Ann Dermatol Venereol; 2020 Nov; 147(11):782-785. PubMed ID: 32653217
[TBL] [Abstract][Full Text] [Related]
23. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
[No Abstract] [Full Text] [Related]
24. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
25. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
26. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC; Suvada J; Dunkel IJ; Casanova M; Zhang W; Ritchie N; Choi Y; Park J; Das Thakur M; Simko S; Wan Rachel Tam N; Ferrari A
Pediatr Blood Cancer; 2018 May; 65(5):e26947. PubMed ID: 29350463
[TBL] [Abstract][Full Text] [Related]
27. Optic pathway glioma in children: 10 years of experience in a single institution.
Doganis D; Pourtsidis A; Tsakiris K; Baka M; Kouri A; Bouhoutsou D; Varvoutsi M; Servitzoglou M; Dana H; Kosmidis H
Pediatr Hematol Oncol; 2016 Mar; 33(2):102-8. PubMed ID: 27007263
[TBL] [Abstract][Full Text] [Related]
28. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
29. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence.
Moreno L; Bautista F; Ashley S; Duncan C; Zacharoulis S
Eur J Cancer; 2010 Aug; 46(12):2253-9. PubMed ID: 20400294
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
31. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma.
Lassaletta A; Guerreiro Stucklin A; Ramaswamy V; Zapotocky M; McKeown T; Hawkins C; Bouffet E; Tabori U
Pediatr Blood Cancer; 2016 Nov; 63(11):2038-41. PubMed ID: 27398937
[TBL] [Abstract][Full Text] [Related]
32. Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening.
Levin MH; Armstrong GT; Broad JH; Zimmerman R; Bilaniuk LT; Feygin T; Li Y; Liu GT; Fisher MJ
Br J Ophthalmol; 2016 Apr; 100(4):510-4. PubMed ID: 26294105
[TBL] [Abstract][Full Text] [Related]
33. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
34. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
35. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
36. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
37. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586
[TBL] [Abstract][Full Text] [Related]
38. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B
Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946
[TBL] [Abstract][Full Text] [Related]
40. Trametinib for progressive pediatric low-grade gliomas.
Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
